No Data
No Data
Shenzhou Cell (688520.SH): Net profit of 74.1974 million yuan in the first quarter
On April 25, Ge Longhui (688520.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 613 million yuan, an increase of 86.30% over the previous year; net profit attributable to shareholders of listed companies of 74.1974 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 157 million yuan; and basic earnings per share of 0.17 yuan.
Sinocelltech Forecasts Return to Profit in Q1
Sinocelltech Group (SHA:688520) forecasts an attributable profit of between 60 million yuan and 80 million yuan in the first quarter, rebounding from a loss of 153 million yuan in the year-ago period.
Shenzhou Cell (688520.SH) made a pre-profit. The net profit for the first quarter is expected to be 60 million yuan to 80 million yuan, changing from loss to profit
Shenzhou Cell (688520.SH) announced that the company expects to become a parent company in the first quarter of 2024...
Shenzhou Cell (688520.SH) announced its 2023 annual results, with a net loss of 396 million yuan, and the loss narrowed
According to Zhitong Finance App News, Shenzhou Cell (688520.SH) released its 2023 annual report. The company's revenue was 1,887 million yuan, up 84.46% year on year; net loss attributable to shareholders of listed companies was 396 million yuan, and losses narrowed; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 63.685 million yuan, which narrowed; basic loss per share was 0.89 yuan/share. During the reporting period, the company's net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss decreased year-on-year, mainly due to a sharp increase in revenue during the reporting period compared to the same period of the previous year.
Sinocelltech's Unit Gets Nod to Trial Tumor Drug
Sinocelltech Group's (SHA:688520) unit, China Cell Engineering, will conduct clinical trials on the SCTB14 injection after receiving approval from China's National Medical Products Administration, acc
Shenzhou Cell (688520.SH): Holding subsidiary product SCTB14 received approval notice for drug clinical trials
On April 10, Ge Longhui Cell (688520.SH) announced that Shenzhou Cell Engineering Co., Ltd., a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to conduct clinical trials for patients with advanced malignant solid tumors, the product SCTB14 injection developed independently by the company. The SCTB14 product is a bispecific antibody injection for multiple solid tumors immunotherapy developed independently by the company with the goal of differentiated competitive advantage.
No Data